Research Topics
| Peter BoyleSummaryAffiliation: International Agency for Research on Cancer Country: France Publications
| Collaborators
|
Detail Information
Publications
A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasiaPeter Boyle
Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
BJU Int 94:83-8. 2004..To investigate the short- and long-term effectiveness of transurethral needle ablation (TUNA) of the prostate for clinical benign prostatic hyperplasia (BPH), using a meta-analysis of all clinical studies involving TUNA...- Curbing tobacco's toll starts with the professionals: World No Tobacco DayPeter Boyle
International Agency for Research on Cancer, Lyon, France
Lancet 365:1990-2. 2005 - Tobacco: deadly in any form or disguisePeter Boyle
International Agency for Research on Cancer, 69372 Lyon, France
Lancet 367:1710-2. 2006 - Mortality and survival in breast and colorectal cancerPeter Boyle
International Agency for Research on Cancer, Lyon, France
Nat Clin Pract Oncol 2:424-5. 2005 - Breast cancer control: signs of progress, but more work requiredPeter Boyle
International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex08, France
Breast 14:429-38. 2005..The declines seen in mortality represent a considerable success, but there is no room for complacency until research can impact positively on reducing incidence... - Estimates of the cancer burden in Europe from radioactive fallout from the Chernobyl accidentElisabeth Cardis
International Agency for Research on Cancer, Lyon, France
Int J Cancer 119:1224-35. 2006.... - The globalisation of cancerPeter Boyle
International Agency for Research on Cancer, 69372 Lyon Cedex, France
Lancet 368:629-30. 2006 - 'Environment' in cancer causation and etiological fraction: limitations and ambiguitiesPaolo Boffetta
International Agency for Research on Cancer, 150 cours Albert-Thomas, 69008 Lyon, France
Carcinogenesis 28:913-5. 2007 - An estimate of cancers attributable to occupational exposures in FrancePaolo Boffetta
International Prevention Research Institute, Lyon, France
J Occup Environ Med 52:399-406. 2010..To perform a quantitative estimate of the proportion of cancers attributable to occupational exposures in France in 2000... - Epidemiology of colorectal cancerPeter Boyle
Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
Br Med Bull 64:1-25. 2002..Achieving colorectal cancer control is the immediate challenge... - Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year resultsUgo Pastorino
Division of Thoracic Surgery, Istituto Nazionale Tumori, Milan, Italy
Lancet 362:593-7. 2003..We investigated the efficacy of repeated yearly spiral CT and selective use of positron emission tomography (PET) in a large cohort of high-risk volunteers... - An estimate of prostate cancer prevalence in ItalyCarlo La Vecchia
Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
Tumori 88:367-9. 2002..The number of clinically detected cases, including cases with advanced disease, is less subject to uncertainty, with reasonable estimates ranging from 45,000 to 60,000... - Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk womenUmberto Veronesi
European Institute of Oncology, Milan, Italy
J Natl Cancer Inst 95:160-5. 2003..Such a strategy would greatly reduce the numbers of women who would need to take tamoxifen to obtain the same absolute reduction in breast cancer. These findings are exploratory and need to be confirmed in other randomized trials... - Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomyUmberto Veronesi
Scientific Directorate, European Institute of Oncology, Milan, Italy
J Natl Cancer Inst 99:727-37. 2007..Here we present an extended follow-up of the Italian trial... - Past medical history and pancreatic cancer risk: Results from a multicenter case-control studyPatrick Maisonneuve
European Institute of Oncology, Milan, Italy
Ann Epidemiol 20:92-8. 2010..To investigate risk factors that may be linked to pancreatic cancer... - Declining mortality from bladder cancer in EuropeJacques Ferlay
International Agency for Research on Cancer, Lyon Cedex, France
BJU Int 101:11-9. 2008.... - Mammographic breast cancer screening: after the dust has settledPeter Boyle
Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
Breast 12:351-6. 2003 - Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trialAndrea Decensi
Divisions of Chemoprevention, European Institute of Oncology, Milan, Italy
Circulation 111:650-6. 2005..Atherosclerosis may induce VTE, or the 2 conditions may share common risk factors. We assessed the effect of tamoxifen on VTE in a breast cancer prevention trial and studied its association with risk factors for VTE... - Tobacco smoking and cancer: a meta-analysisSara Gandini
Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
Int J Cancer 122:155-64. 2008..The analysis of heterogeneity showed that study type, gender and adjustment for confounding factors significantly influence the RRs estimates and the reliability of the studies... - The future of the nicotine-addiction marketNigel Gray
Division of Epidemiology and Biostatistics, European Institute of Oncology, 20141, Milan, Italy
Lancet 362:845-6. 2003 - Relation of childhood brain tumors to exposure of parents and children to tobacco smoke: the SEARCH international case-control study. Surveillance of Environmental Aspects Related to Cancer in HumansGraziella Filippini
Neuroepidemiology Research Unit, Istituto Nazionale Neurologico C Besta, Milan, Italy
Int J Cancer 100:206-13. 2002..These results did not change considering the child's age at diagnosis, the histologic type of tumor or center... - Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposureSara Gandini
Department of Epidemiology and Biostatistics, European Institute of Oncology, IRCCS Via Ripamonti 435, 20141 Milan, Italy
Eur J Cancer 41:45-60. 2005.... - ELAC2/HPC2 polymorphisms, prostate-specific antigen levels, and prostate cancerGianluca Severi
Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
J Natl Cancer Inst 95:818-24. 2003..In five of the seven total studies, subject selection was influenced by prostate-specific antigen (PSA) levels. We examined the association and possible effect of subject selection in a larger study and a meta-analysis... - Breast cancerUmberto Veronesi
European Institute of Oncology, Milan, Italy
Lancet 365:1727-41. 2005..Assessment of potential molecular targets is now important in primary diagnosis. Tyrosine-kinase inhibitors and other drugs with anti-angiogenesis properties are currently undergoing preclinical investigations... - Testicular cancer: the challenge for cancer controlPeter Boyle
Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
Lancet Oncol 5:56-61. 2004..Testicular cancer control would be the finest illustration of this process and, simultaneously, would be a model for implementation as new, successful therapeutic modalities for other cancers are developed... - Artificial ultraviolet sources and skin cancers: rationale for restricting access to sunbed use before 18 years of agePhilippe Autier
International Agency for Research, Lyon, France
Nat Clin Pract Oncol 5:178-9. 2008 - The role of the dental team in preventing and diagnosing cancer: 1. cancer in generalCrispian Scully
Eastman Dental Institute for Oral Health Care Sciences, University College London, 256 Gray's Inn Road, London WC1X 8LD
Dent Update 32:204-6, 208-10, 212. 2005..The signs and symptoms of cancer often resemble less serious conditions and prompt referral to an appropriate specialist usually allows for the best management... - Screening for prostate cancer: updated experience from the Tyrol studyWolfgang Horninger
Department of Urology, University of Innsbruck, Innsbruck, Austria
Can J Urol 12:7-13; discussion 92-3. 2005.... - The challenge of cancer control in AfricaRebecca J Lingwood
Department for Continuing Education, University of Oxford, Littlegate House, 16 17 St Ebbes street, Oxford, OX1 1PT, UK
Nat Rev Cancer 8:398-403. 2008..Many of these cancers are preventable, or treatable when detected early enough. Establishing effective, affordable and workable cancer control plans in African countries is one step in the right direction toward limiting this epidemic... - Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)Raymond Rosen
Department of Psychiatry, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA
Eur Urol 44:637-49. 2003..This study was conducted to investigate the relationship between LUTS and sexual problems in aging men... - Recent trends in mortality from benign prostatic hyperplasiaFabio Levi
Cancer Epidemiology Unit and Cancer Registries of Vaud and Neuchâtel, Institut Universitaire de Medecine Sociale et Preventive, CHUV Falaises 1, 1011 Lausanne, Switzerland
Prostate 56:207-11. 2003..We have considered trends in mortality from benign prostatic hyperplasia (BPH) over the last decades in Europe and, for comparative purposes, the USA and Japan... - Cigarette smoking, glutathione-s-transferase M1 and t1 genetic polymorphisms, and breast cancer risk (United States)Tongzhang Zheng
Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06510, USA
Cancer Causes Control 13:637-45. 2002..We sought to determine if there is a gene-environment interaction between GSTM I (GSTM1A and GSTM1B), and GSTT1 genotypes and cigarette smoking in the risk of breast cancer... - Leveling of prostate cancer mortality in Western EuropeFabio Levi
Cancer Epidemiology Unit and Cancer Registries of Vaud and Neuchâtel, Institut Universitaire de Medecine Sociale et Preventive, Lausanne, Switzerland
Prostate 60:46-52. 2004..Trends in 24 European countries, the European Union (EU), six selected Central and Eastern European countries, and the Russian Federation have been updated to 1999... - Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New ZealandJohn H Stewart
Department of Medical and Surgical Sciences, University of Otago, Dunedin, New Zealand
J Am Soc Nephrol 14:197-207. 2003.... - [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]Frans Debruyne
Hôpital Universitaire Saint Radboud, Nijmegen, Pays Bas
Prog Urol 14:326-31. 2004..To compare the efficacy of the lipido-sterolic extract of Serenoa repens, Permixon, to that of the a-blocker, tamsulosin, in the treatment of severe low urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH)... - 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopeciaVanessa M Hayes
Cancer Research Program, Garvan Institute of Medical Research, St Vincent s Hospital, Sydney, Australia
Int J Cancer 120:776-80. 2007..These findings raise important questions with respect to previous assumptions concerning hormonal influences on prostate cancer risk in ageing males... - Testicular cancer mortality in Eastern EuropeFabio Levi
Int J Cancer 105:574. 2003 - A new face at the IARCEmma Wilkinson
Lancet Oncol 4:386. 2003 - Ultraviolet radiation exposure and risk of non-Hodgkin's lymphomaYawei Zhang
Yale University School of Epidemiology and Public Health, New Haven, CT 06520 8034, USA
Am J Epidemiol 165:1255-64. 2007..0051). The risk appears to vary by non-Hodgkin's lymphoma subtypes. Further investigations of the role of ultraviolet radiation on the risk of non-Hodgkin's lymphoma are warranted... - Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trialRoger S Kirby
St. George's Hospital, London, United Kingdom
Urology 61:119-26. 2003..The addition of finasteride did not provide further benefit to that achieved with doxazosin alone... - Androgenetic alopecia and prostate cancer: findings from an Australian case-control studyGraham G Giles
Cancer Epidemiology Centre, Anti-Cancer Council of Victoria, Melbourne, VIC 3053 Australia
Cancer Epidemiol Biomarkers Prev 11:549-53. 2002..91 (1.59-5.32) for vertex baldness; and 1.95 (1.10-3.45) for frontal and vertex baldness. This association between the pattern of AA and prostate cancer points to shared androgen pathways that are worthy of additional investigation... - Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasiaClaus G Roehrborn
Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9110, USA
Urology 60:434-41. 2002.... - The changing pattern of kidney cancer incidence and mortality in EuropeFabio Levi
Unité d épidemiologie du cancer et Registres des tumeurs de Vaud et Neuchâtel, Institut de Medecine Sociale et Preventive, Centre Hospitalier Universitaire Vaudois et Universite de Lausanne, Lausanne, Switzerland
BJU Int 101:949-58. 2008.... - [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]Frans Debruyne
Academic Hospital Nijmegen, Nijmegen Sint Radboud, Pays-Bas
Prog Urol 12:384-92; discussion 394-4. 2002..CONCLUSION: This study demonstrated that Permiwon and tamsulosin are equivalent in the medical treatment of lower urinary tract symptoms in men with BPH, during and up to 12 months of therapy... - Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international studyFrans Debruyne
Academic Hospital Nijmegen Sint Radboud, Nijmegen, The Netherlands
Eur Urol 41:497-506; discussion 506-7. 2002..CONCLUSION: This study demonstrates that Permixon and tamsulosin are equivalent in the medical treatment of lower urinary tract symptoms in men with BPH, during and up to 12 months of therapy... - Is FOB screening really the answer for lowering mortality in colorectal cancer?Philippe Autier
Centre for Research in Epidemiology (CRESIS, Luxembourg Health Institute, Luxembourg, Luxembourg
Recent Results Cancer Res 163:254-63; discussion 264-6. 2003..Therefore, recommending general population screening with biennial FOBT is still an open question... - Measures of familial aggregation depend on definition of family history: meta-analysis for colorectal cancerLaura Baglietto
Cancer Epidemiology Centre, The Cancer Council of Victoria, 100 Rathdowne Street, Carlton, Melbourne, Victoria 3053, Australia
J Clin Epidemiol 59:114-24. 2006.... - Screening for prostate cancer: updated experience from the Tyrol studyWolfgang Horninger
Department of Urology, University of Innsbruck, Anichstrasse 35, A 6020 Innsbruck, Austria
Curr Urol Rep 5:220-5. 2004..It is our opinion that most of this decline is likely a result of aggressive downstaging and successful treatment and that any contribution from detecting and treating early cancers will become apparent in the years to come... - Menstrual and reproductive factors and risk of non-Hodgkin's lymphoma among Connecticut womenYawei Zhang
Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT, USA
Am J Epidemiol 160:766-73. 2004..These findings support a reduced risk of non-Hodgkin's lymphoma associated with multiple pregnancies and an increased risk of non-Hodgkin's lymphoma associated with later age at menarche... - Publishing tobacco tar measurements on packetsNigel Gray
BMJ 329:813-4. 2004 - Serum polychlorinated biphenyls, cytochrome P-450 1A1 polymorphisms, and risk of breast cancer in Connecticut womenYawei Zhang
Department of Epidemiology and Public Health, School of Medicine, Yale University, New Haven, CT 06510, USA
Am J Epidemiol 160:1177-83. 2004..In summary, the CYP1A1 m2 genetic polymorphism was associated with increased risk of female breast cancer and may modify the relation between PCB exposure and breast cancer risk... - Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naeviSara Gandini
Department of Epidemiology and Biostatistics, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy
Eur J Cancer 41:28-44. 2005..Case-control studies, in particular when the hospital was the source for cases or controls, appeared to present much lower and more precise estimates than cohort studies... - Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysisFrans Debruyne
Department of Urology, Academic Hospital Nijmegen, Geert Grooteplein Zuid 16, 426 Afdeling Urologie, 6500 HB Nijmegen, The Netherlands
Eur Urol 45:773-9; disucssion 779-80. 2004..To compare the efficacy of the lipido-sterolic extract of Serenoa repens, Permixon, to that of the alpha-blocker, tamsulosin, in the treatment of severe low urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH)... - [Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging.male (MSAM-7)]Raymond Rosen
Service de Psychiatrie, Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA
Prog Urol 14:332-44. 2004..This study was conducted to investigate the relationship between LUTS and sexual problems in aging men... - Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960Fabio Levi
Unité d Epidémiologie du Cancer and Registres Vaudois et Neuchâtelois des Tumeurs, Institut Universitaire de Medecine Sociale et Preventive, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Int J Cancer 110:155-69. 2004..Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html.. - Cancer of the skin: a forgotten problem in EuropePeter Boyle
Ann Oncol 15:5-6. 2004 - Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factorsSara Gandini
Department of Epidemiology and Biostatistics, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141 Milan, Italy
Eur J Cancer 41:2040-59. 2005..Sensitivity analyses investigated reliability of results and publication bias. Latitude and adjustment for phenotype were two study characteristics that significantly influenced the estimates... - A putative exonic splicing polymorphism in the BCL6 gene and the risk of non-Hodgkin lymphomaYawei Zhang
Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, CT 06520 8034, USA
J Natl Cancer Inst 97:1616-8. 2005..2, 95% CI = 2.0 to 13.3). Our results support the hypothesis that a genetic variant that could alter mRNA transcripts of BCL6 may contribute to the etiology of NHL and suggest that this variant warrants further investigation... - Tobacco control, screening, and collaboration are priorities for IARC, incoming director says. Interview with Peter BoylePeter Boyle
J Natl Cancer Inst 95:1653-5. 2003 - Alcohol use and risk of non-Hodgkin's lymphoma among Connecticut women (United States)Lindsay McOmber Morton
Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06520, USA
Cancer Causes Control 14:687-94. 2003..The reduction in risk of NHL associated with increased duration of wine consumption warrants further investigation in other populations... - Circulating steroid hormones and the risk of prostate cancerGianluca Severi
Cancer Epidemiology Centre, The Cancer Council Victoria, University of Melbourne, Melbourne, Australia
Cancer Epidemiol Biomarkers Prev 15:86-91. 2006..06, 0.2, and 0.1, respectively). High levels of testosterone and adrenal androgens are thus associated with reduced risk of aggressive prostate cancer but not with nonaggressive disease...